Opthea (OPT) - The BREAKTRHOUGH in Vision Treatment IMMINENT, page-7

Hi FFS,

Just a little addition to you point regarding repayment of DVA:
Given the information on page 32 / slide 35 in the latest Annual Report (=> click here <=) I would not expect the first of the seven fixed success payment (the one happening after approval but before commercialization) to be particularly high, maybe some US$50M. But that‘s just a guess…

And equally important, definitely not due before approval some time in 3Q CY2026 (my modeling) or 4Q CY2026 (company’s guidance).

So plenty of time for OPT to develop into a valuation when the actual repayment of DVA becomes a pretty negligible topic in the mind of management and investors like us.